Skip to main content
. 2020 Oct 20;95(16):e2295–e2304. doi: 10.1212/WNL.0000000000010643

Figure 1. Rates of progression to mild cognitive impairment (MCI).

Figure 1

Progression to MCI over 10 years as a function of anticholinergic (ACH) medication use and (A) APOE ε4 status (ε4− or ε4+) or (B) CSF Alzheimer disease [AD] pathology (β-amyloid [Aβ]/phosphorylated-tau [p-tau]− or Aβ/p-tau+).